Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan
• Sustained disease control at 12 weeks has improved to 80%• Consistent anti-tumor activity, >75% of patients experiencing tumor shrinkage in target lesions • Continued good safety and tolerability profile. Longest running patient still on treatment after 16 months with sustained partial response Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today improved durable clinical benefit in maturing data from the ongoing phase 1b/2a study in